Ubs Group Ag Dia Medica Therapeutics Inc. Transaction History

Ubs Group Ag

$555 Billion
Q2 2025

A detailed history of Ubs Group Ag transactions in Dia Medica Therapeutics Inc. stock. As of the latest transaction made, Ubs Group Ag holds 8,266 shares of DMAC stock, worth $43,148. This represents 0.0% of its overall portfolio holdings.

Number of Shares

8,266

Previous 4,382 88.64%

Holding current value

$43,148

Previous $16,000 100.0%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$3.38 - $4.64 $13,127 - $18,021	3,884 Added 88.64%	8,266 $32,000
Q1 2025 May 13, 2025	BUY	$3.79 - $6.65 $9,903 - $17,376	2,613 Added 147.71%	4,382 $16,000
Q4 2024 Feb 14, 2025	SELL	$4.01 - $5.45 $43,989 - $59,786	-10,970 Reduced 86.11%	1,769 $9,000
Q3 2024 Nov 14, 2024	BUY	$2.8 - $4.49 $35,669 - $57,198	12,739 New	12,739 $53,000
Q1 2024 May 13, 2024	BUY	$2.58 - $3.23 $4,969 - $6,220	1,926 New	1,926 $5,000
Q3 2023 Nov 09, 2023	BUY	$2.56 - $4.4 $215 - $369	84 New	84 $0
Q1 2023 May 12, 2023	SELL	$1.32 - $1.89 $2,269 - $3,248	-1,719 Reduced 45.75%	2,038 $3,000
Q4 2022 Feb 08, 2023	SELL	$1.13 - $1.62 $3,880 - $5,563	-3,434 Reduced 47.75%	3,757 $5,000
Q3 2022 Nov 10, 2022	BUY	$1.2 - $2.07 $4,993 - $8,613	4,161 Added 137.33%	7,191 $9,000
Q2 2022 Aug 10, 2022	BUY	$1.86 - $2.62 $3,868 - $5,449	2,080 Added 218.95%	3,030 $6,000
Q1 2022 May 16, 2022	SELL	$2.29 - $3.88 $8,399 - $14,231	-3,668 Reduced 79.43%	950 $2,000
Q4 2021 Feb 14, 2022	BUY	$3.43 - $4.65 $15,839 - $21,473	4,618 New	4,618 $17,000
Q3 2021 Nov 15, 2021	SELL	$3.1 - $4.32 $64,216 - $89,488	-20,715 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$4.45 - $9.91 $87,509 - $194,880	19,665 Added 1872.86%	20,715 $92,000
Q1 2021 May 12, 2021	BUY	$7.76 - $10.43 $1,055 - $1,418	136 Added 14.88%	1,050 $10,000
Q4 2020 Feb 11, 2021	BUY	$4.13 - $10.14 $3,774 - $9,267	914 New	914 $9,000
Q3 2020 Nov 12, 2020	SELL	$3.91 - $7.15 $2,302 - $4,211	-589 Closed	0 $0
Q2 2020 Jul 31, 2020	SELL	$2.6 - $7.32 $20,568 - $57,908	-7,911 Reduced 93.07%	589 $4,000
Q1 2020 May 01, 2020	BUY	$2.25 - $5.64 $19,125 - $47,940	8,500 New	8,500 $24,000
Q4 2019 Feb 14, 2020	SELL	$1.8 - $5.04 $4,237 - $11,864	-2,354 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$2.07 - $4.88 $215 - $507	104 Added 4.62%	2,354 $5,000
Q2 2019 Aug 14, 2019	BUY	$2.7 - $4.96 $6,075 - $11,160	2,250 New	2,250 $11,000
Q1 2019 May 14, 2019	SELL	$3.1 - $4.54 $4,101 - $6,006	-1,323 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$2.65 - $9.2 $3,505 - $12,171	1,323 New	1,323 $4,000

Others Institutions Holding DMAC

# of Institutions

Shares Held

5.97M

Call Options Held

14.1K

Put Options Held

View Full List

About DiaMedica Therapeutics Inc.

Ticker DMAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,443,100
Market Cap $138M
Description
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...

More about DMAC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account